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Herpes zoster (HZ) can have a substantial impact on quality of life (QoL). The vaccine efﬁcacy (VE) of a recombinant
zoster vaccine (RZV) was 68.2% (95% conﬁdence interval [CI], 55.6% to 77.5%) in a phase 3 study in adult autologous
hematopoietic stem cell transplant (HSCT) recipients (NCT01610414). Herein, we report the impact of RZV on
patients’ QoL. Autologous HSCT recipients were randomized 1:1 to receive 2 doses of RZV or placebo, given 1 to 2
months apart. QoL was measured by the Short Form Survey-36 and Euro-QoL-5 Dimension at baseline, 1 month,
and 1 year postdose 2 and during suspected HZ episodes with the Zoster Brief Pain Inventory (ZBPI). The RZV impactKeywords:
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D. Curran et al. / Biol Blood Marrow Transplant 25 (2019) 24742481 2475on ZBPI burden of illness and burden of interference scores was estimated. The 2 scores were calculated from the
area under the curve (days 0 to 182) of the ZBPI worst pain and ZBPI activities of daily living scores, respectively,
assuming a score of 0 for patients not having a conﬁrmed HZ episode. The ZBPI maximum worst pain score was sig-
niﬁcantly lower in the RZV than placebo group (mean: 5.8 versus 7.1, P = .011). Consequently, the VE estimates for
HZ burden of illness (82.5%; 95% CI, 73.6 to 91.4) and burden of interference (82.8%; 95% CI, 73.3 to 92.3) were higher
than the HZ VE estimate (ie, 68.2%). RZV showed signiﬁcantly better QoL scores than placebo 1 week following rash
onset among patients with conﬁrmed HZ. In addition to reducing the risk of HZ and its complications, RZV signiﬁ-
cantly reduced the impact of HZ on patients’ QoL in those who developed breakthrough disease.
© 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Quality of life
Recombinant zoster vaccine
VaccinationINTRODUCTION
Herpes zoster (HZ), which occurs following the reactivation
of latent varicella zoster virus (VZV), usually presents as a
painful vesicular dermatomal rash [1,2]. VZV cell-mediated
immunity, which inhibits the development of HZ, can decline
for a number of reasons, including increasing age and immune
suppression [3,4]. Patients with malignant, chronic, or autoim-
mune conditions, or those receiving immunosuppressive ther-
apies, therefore have an increased risk of developing HZ [5].
Hematopoietic stem cell transplantation is the risk factor with
the highest odds ratio for developing HZ (odds ratio, 13.46)
[5]. Several studies reported an increased risk of HZ among
stem cell transplant recipients, with incidence rates reaching
41.7 per 1000 person years [6-10].
In addition to the increased risk of HZ in patients with vari-
ous immunocompromising conditions, these individuals also
experience an increased severity of disease. For example, high
proportions of hematopoietic stem cell transplant (HSCT)
recipients develop complications, including postherpetic neu-
ralgia following HZ [11,12].
In a study in Canada, Drolet et al. [13] reported that individu-
als with an impaired immune status had HZ severity of illness
scores, as measured by the Zoster Brief Pain Inventory (ZBPI),
that were twice as high as individuals with normal immune func-
tion. In a study in the United States, Yawn et al. [14] reported that
although 8% of HZ cases occurred among immunocompromised
patients, these individuals represented 23.8% of the total HZ-
related costs. Another study, based on data from the United King-
dom, demonstrated that the highest direct medical costs related
to patients with HZ were observed in HSCT recipients [15].
Prevention of HZ in HSCT recipients is traditionally achieved
using oral acyclovir or valacyclovir. However, as there is still a
high risk of HZ once treatment is stopped, the optimal duration of
prophylaxis remains unclear [8,16,17]. A live-attenuated vaccine
produced by Merck (Zostavax, New Jersey, United States) is
licensed to prevent HZ in immunocompetent adults aged
50 years. However, the vaccine is contraindicated in immuno-
compromised individuals, in whom administration may result in
disseminated disease. Recently, a nonlive 2-dose adjuvanted
recombinant zoster vaccine (RZV) produced by GlaxoSmithKline
(Shingrix, United Kingdom) was licensed in adults aged50 years
[18]. This vaccine consists of the VZV glycoprotein E antigen and
an adjuvant system (AS01B). The vaccine efﬁcacy (VE) in prevent-
ing HZ in immunocompetent individuals was 97.2% in adults
50 years and 91.3% in older adults70 years [19,20].
This phase III ZOster Efﬁcacy trial in HSCT recipients
(NCT01610414; ZOE-HSCT) was designed to explore the
impact of RZV (2 doses administered 1 to 2 months apart start-
ing 50 to 70 days post-transplantation) on reducing the burden
of HZ in autologous HSCT recipients. The efﬁcacy, safety, and
immunogenicity results of the study are published elsewhere
[21]; only the quality-of-life (QoL) results are presented here.
The VE of RZV in preventing HZ in adult autologous HSCTrecipients was 68.2% (95% conﬁdence interval [CI], 55.6% to
77.5%). In this article, we present further results from the ZOE-
HSCT trial concerning the impact of RZV on the burden of HZ
illness, the burden of HZ interference on patients’ activities of
daily living (ADLs), and the effect of HZ on patients’ QoL.
MATERIALS ANDMETHODS
This randomized, placebo-controlled, phase III multicenter study
assessed the efﬁcacy, immunogenicity, and safety of RZV in autologous HSCT
recipients aged 18 years. The study design has been described in detail in
the study presenting the efﬁcacy and safety results of the trial [21].
Outcome Measures
The ZBPI questionnaire asks the participant to rate 4 categories of pain
(least, worst, and average “in the last 24 hours,” in addition to “right now”) on
11-point Likert-type scales (0 to 10, with 10 signifying the worst imaginable
pain). The ZBPI also assesses the degree to which HZ pain interfered with 7
ADLs: general activity, mood, walking ability, work, relation with others, sleep,
and enjoyment of life. These were all rated on 11-point Likert-type scales, with
0 signifying “does not interfere” and 10 “completely interferes.” A summary
ADL score was calculated by averaging the scores for all 7 activities.
Autologous HSCT recipients with suspected HZ were asked to complete the
ZBPI at home every day from rash onset until the ﬁrst visit to the site. They com-
pleted a ZBPI on site at this visit, at home for the next 28 days, and weekly there-
after until either they had been pain free for 4 consecutive weeks or 90 days had
elapsed since the onset of the rash (whichever came last). For all analyses of data
involving HZ episodes, day 0 was deﬁned as the ﬁrst day of HZ rash [22].
EuroQol-5 Dimension (EQ-5D) is a utility instrument widely used to
assess individuals’ health-related QoL. Autologous HSCT recipients were
asked to grade the extent of their problems (no problem, some problems,
and severe problems) in 5 dimensions: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. The combination of answers to the
5 dimensions results in 243 possible health states, each of which could be
translated into a utility score ranging from below 0 (a health state worse
than death) to 1 (best possible health state) [23]. QoL was also assessed using
the Short Form Survey-36 (SF-36) [24]. The SF-36 is a self-reported multidi-
mensional instrument designed to assess overall health status and QoL. It
consists of 36 questions covering 8 domains: physical function, physical role,
general health, bodily pain, mental health, social functioning, vitality/fatigue,
and emotional role. Responses from these domains are subsequently summa-
rized into 2 component scores: physical and mental.
All autologous HSCT recipients completed the EQ-5D and SF-36 question-
naires at baseline (ie, before vaccination dose 1). Autologous HSCT recipients
who did not develop HZ also completed the questionnaires at 1 month and 1
year postvaccination, whereas all those experiencing a suspected HZ episode
completed both the EQ-5D and SF-36 weekly during the entire period that
the ZBPI questionnaires were completed.
Statistical Analyses
For each case of HZ, the maximal ZBPI worst and average pain scores during
the HZ episode were calculated and compared between the RZV and placebo
groups bymeans of the Wilcoxon nonparametric test. Clinically signiﬁcant pain
was deﬁned as a ZBPI worst pain score greater than or equal to 3.
The ZBPI severity of illness scores were calculated as the area under the
curve (AUC) of the ZBPI worst pain score from day 0 until day 182 [22]. A
ZBPI severity of illness score of 0 was imputed for autologous HSCT recipients
without conﬁrmed HZ. The burden of illness due to pain was then estimated
by aggregating the severity of illness scores over all the autologous HSCT
recipients in a group and dividing by the total number of years of participant
follow-up. Consequently, this composite measure took into account the inci-
dence of HZ as well as the severity and duration of HZ pain.
VE was deﬁned as the relative reduction in the burden of illness score in
the RZV group compared with the score in the placebo group and calculated
as 1 minus the relative risk (ie, the burden of illness score in the RZV group
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ing the burden of interference was deﬁned and calculated in a similar way
using the composite ZBPI ADL score as the measure.
These analyses were performed on the modiﬁed Total Vaccinated Cohort
(mTVC), which excluded autologous HSCT recipients who did not receive 2
doses or who had a conﬁrmed HZ episode within 1 month of receiving dose
2, and included only patients with HZ who completed at least 1 ZBPI ques-
tionnaire. The Chop-Lump [25] test was used to assess the difference in ZBPI
severity of illness scores and ZBPI severity of interference scores between the
RZV and placebo groups in the mTVC cohort.
The VE for reducing severe ZBPI pain (score 7 for worst pain) was esti-
mated in the ZBPI evaluable subgroup, which comprised autologous HSCT
recipients in the mTVC with conﬁrmed HZ cases who had completed a ZBPI
questionnaire during the ﬁrst 14 days after HZ onset. Standardized asymp-
totic binomial CIs for the VE were calculated using the score method of Far-
rington and Manning [26].
A repeated-measures analysis of variance model (ANOVA)was ﬁtted includ-
ing terms for region, age, sex, and a vaccine-by-time (window) interaction [27].Figure 1. Flowchart for the ZOE-HSCT study. mTVC: excluded autologous HSCT recip
within 1 month of receiving dose 2. mTVC ZBPI evaluable HZ cases: included HZ conﬁ
postrash onset.The least squares mean estimates for time by vaccine effects were obtained
from the ANOVAmodel. The associated differences in least squares means and P
values were also estimated. A multivariate rank analysis of repeated-measures
ordinal categorical data was carried out using the Wei-Lachin method, which
assumes that missing data are missing at random [28]. A repeated-measures
ANOVA model was ﬁtted to estimate the impact of HZ on EQ-5D utility scores in
the placebo group only, stratiﬁed by age. The model included the baseline utility
scores (ie, the most recent utility assessment before the onset of HZ and the util-
ity scores during the ﬁrst 4 weeks of the HZ episode).RESULTS
Most participants in the TVC were white (78.4%), male
(62.7%), and aged 50 years (75.1%). At a median follow-up of
21 months, 49 conﬁrmed HZ cases had occurred among the
870 autologous HSCT recipients receiving RZV compared with
135 among the 851 receiving placebo in the mTVC (Figure 1).ients who did not receive 2 doses of RZV or who had a conﬁrmed HZ episode
rmed cases in participants who completed a ZBPI questionnaire within 14 days
Table 1
Demographics of the Participants Developing HZ
Characteristic RZV (n = 49) Placebo (n = 135)
Age, yr
Mean 56.0 56.6
Range 24-69 23-72
Sex, n (%)
Female 16 (32.7) 61 (45.2)
Male 33 (67.3) 74 (54.8)
Ancestry, n (%)
African heritage/African
American
0 4 (3.0)
Asian: East Asian heritage 1 (2.0) 16 (11.9)
Asian: Japanese heritage 1 (2.0) 12 (8.9)
Asian: Southeast Asian heritage 0 1 (0.7)
White: Caucasian/European
heritage
45 (91.8) 99 (73.3)
Other 2 (4.1) 3 (2.2)
Figure 2. Mean ZBPI worst pain (A) and ADL scores (B) per day during the ﬁrst
28 days after rash onset (mTVC HZ conﬁrmed CasesZBPI evaluable subgroup).
Table 2
Distribution of Maximal ZBPI Worst Pain and ZBPI Average Pain Scores over
the Duration of the Entire HZ Episode (mTVC Cohort HZ Conﬁrmed CasesZBPI
Evaluable Subgroup*)
Worst Pain Average Pain
ZBPI Score RZV
(n = 44)
Placebo
(n = 125)
RZV
(n = 44)
Placebo
(n = 125)
3 36 (81.8) 115 (92.0) 34 (77.3) 109 (87.2)
7 21 (47.7) 86 (68.8) 10 (22.7) 55 (44.0)
0 4 (9.1) 3 (2.4) 4 (9.1) 3 (2.4)
1 1 (2.3) 2 (1.6) 2 (4.5) 7 (5.6)
2 3 (6.8) 5 (4.0) 4 (9.1) 6 (4.8)
3 2 (4.5) 6 (4.8) 4 (9.1) 9 (7.2)
4 4 (9.1) 3 (2.4) 6 (13.6) 9 (7.2)
5 5 (11.4) 9 (7.2) 7 (15.9) 17 (13.6)
6 4 (9.1) 11 (8.8) 7 (15.9) 19 (15.2)
7 7 (15.9) 16 (12.8) 4 (9.1) 31 (24.8)
8 4 (9.1) 29 (23.2) 0 10 (8.0)
9 5 (11.4) 22 (17.6) 5 (11.4) 8 (6.4)
10 5 (11.4) 19 (15.2) 1 (2.3) 6 (4.8)
P valuey .0111 .0183
Mean 5.8 7.1 4.7 5.7
SD 3.06 2.54 2.70 2.44
Values are presented as n (%) unless otherwise indicated.
* Includes only autologous HSCT recipients in the mTVC HZ conﬁrmed case-
ZBPI evaluable subgroup (ie, conﬁrmed HZ cases with a ZBPI questionnaire
completed during the ﬁrst 14 days after rash onset).
y P value is based on the Wilcoxon test.
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who developed conﬁrmed HZ are presented Table 1. The mean
ages of both groups were similar, but there were proportion-
ally more males and more whites in the RZV group.
The mean time between the onset of rash and ﬁrst HZ eval-
uation was 2.8 (range, 0 to 16) and 3.4 (range, 0 to 29) days in
the RZV and placebo groups, respectively. Completion rates for
the ZBPI questionnaire were approximately 40% on day 0,
>60% from day 3 onward, and 80% from day 6 onward. The
mTVC HZ conﬁrmed caseZBPI evaluable subgroup, comprised
44 RZV and 125 placebo autologous HSCT recipients. The com-
pletion rate of the EQ-5D and SF-36 instruments during an
ongoing HZ episode was approximately 50% on day 0 and
77% at all time points thereafter.
ZBPI
Figure 2 displays the mean ZBPI worst pain scores
(Figure 2A) and ADL scores (Figure 2B) per day during the ﬁrst
28 days after rash onset for the mTVC HZ conﬁrmed caseZBPI
evaluable subgroup. The mean ZBPI worst pain and ADL scores
were lower in the RZV group than in the placebo group at all
time points (overall Wei-Lachin test P = .003 and P = .012,
respectively). This observation was relatively consistent for all
of the ZBPI ADL individual items (ie, ZBPI general activity
score: P = .009, ZBPI mood score: P = .067, ZBPI walking ability
score: P = .002, ZBPI normal work score: P = .003, ZBPI relations
score: P = .022, ZBPI sleep score: P = .018, ZBPI enjoyment of
life score: P = .046, data not shown).
Table 2 presents the distribution of the individual maxi-
mal ZBPI worst pain and average pain scores experienced
over the entire HZ episode. A severe ZBPI worst pain score
(ie, 7) was reported by 47.7% of the RZV group and 68.8% of
placebo HZ cases (VE, 30.6%; 95% CI, 6.7% to 51.8%). The cor-
responding proportions reporting severe average pain were
22.7% and 44.0%, respectively (VE, 48.4%; 95% CI, 11.9% to
71.7%). The median time to resolution of clinically signiﬁcant
pain was 20 days in the RZV group and 31 days in the pla-
cebo group (P = .048).
Table 3 presents the mean AUC for the ZBPI worst pain
and ADL scores. For all time periods, the AUC of the ZBPI
worst pain score was statistically signiﬁcantly lower in the
RZV group compared with placebo (P  .004). Similarly, theAUC of the ZBPI ADL scores was statistically signiﬁcantly
lower in the RZV group compared with placebo (P  .014 for
all time periods).
Table 3
Vaccine Efﬁcacy in Reducing the HZ Disease Impact as Measured by the Worst Pain and Activities of Daily Living Scores (mTVC Conﬁrmed CasesHZ ZBPI Evaluable
Subgroup)
ZBPI Worst Pain Score ZBPI ADL Score
AUC RZV (n = 44) Placebo (n = 125) P Value* Vaccine Efﬁcacy, % RZV (n = 44) Placebo (n = 125) P Value* Vaccine Efﬁcacy, %
30 days
Mean 77.52 115.69 .003 33.0 49.73 75.92 .012 34.5
SD 66.34 72.50 53.63 65.56
90 days
Mean 103.89 167.74 .004 38.1 69.52 114.06 .014 39.0
SD 123.31 150.63 97.12 126.65
182 days
Mean 105.28 186.94 .003 43.7 70.17 125.78 .014 44.2
SD 128.29 211.97 97.88 160.64
mTVC: excluded autologous hematopoietic stem cell transplant recipients who did not receive 2 doses of RZV or who had a conﬁrmed HZ episode within 1 month of
receiving dose 2.
mTVC ZBPI evaluable HZ cases: included HZ conﬁrmed cases in participants who completed a ZBPI questionnaire within 14 days after rash onset.
* P value is based on the Wilcoxon test.
Figure 3. Estimated mean EQ-5D utility scores during the ﬁrst 28 days after
rash onset (mTVC HZ conﬁrmed cases). An EQ-5D value of 1 represents the
best possible health state. Diff (CI), difference (CI).
2478 D. Curran et al. / Biol Blood Marrow Transplant 25 (2019) 24742481SF-36 and EQ-5D
The QoL scores by SF-36 tended to be higher in the RZV
group compared with placebo. For example, at week 1 post HZ
rash onset, when the greatest differences were observed, sta-
tistically signiﬁcant differences in favor of RZV (P < .05) were
observed for the SF-36 bodily pain, social functioning, role
emotional, mental health, and mental component scores
(Table 4).
The estimated mean EQ-5D utility scores over time are
shown in Figure 3. The differences between RZV and placebo
groups were greatest at week 1 and decreased over time. At
week 1, the EQ-5D utility score was signiﬁcantly higher in the
RZV group compared with placebo (P = .0021).
The estimated utility loss of autologous HSCT recipients in
the placebo group, who developed HZ over the ﬁrst 28 days
after rash onset, is presented by age (ie, 18 to 49 and 50
years) in Table 5. The utility loss was highest on day 0 and
decreased over time in both age groups as the autologous
HSCT recipients recovered from HZ. Nevertheless, a negative
impact of HZ on QoL remained until the end of week 4.
Vaccine Efﬁcacy
As seen in Table 6, the overall VE estimate for the burden of
illness score was 82.5% (95% CI, 73.6% to 91.4%) with pointTable 4
SF-36 and EQ-5D Domains at Week 1 (mTVC HZ Conﬁrmed Cases)
Domain RZV* (n = 49) Placebo* (n = 135)
Physical functioning 64.21 60.41
Physical role 58.45 49.32
Bodily pain 53.18 39.85
General health 47.05 48.22
Vitality 49.76 43.92
Social functioning 68.81 55.88
Role emotional 77.62 67.13
Mental health 74.44 66.69
PCS 41.14 39.62
MCS 49.08 44.10
EQ-5D utility score 0.7075 0.5670
EQ-5D VAS score 67.7 63.5
MCS indicates mental health component score; PCS, physical health component score;
* Least squares means.
y P value is based on the difference in least squares means taken from the repeated-estimates of 83.4 and 82.4 in the 18 to 49 and 50 years age
groups, respectively. The overall VE estimate for the burden of
interference score was 82.8% (95% CI, 73.3% to 92.3%) with
point estimates of 79.6 and 83.6 in the 18 to 49 and 50 years
age groups, respectively.Difference Conﬁdence Interval P Valuey
3.80 (5.29, 12.89) .4122
9.13 (1.06, 19.32) .0790
13.33 (4.38, 22.28) .0035
1.17 (7.94, 5.60) .7350
5.84 (2.24, 13.91) .1566
12.93 (3.99, 21.87) .0046
10.49 (0.99, 19.98) .0304
7.75 (0.59, 14.91) .0339
1.52 (1.51, 4.56) .3252
4.97 (1.22, 8.73) .0095
0.140 (0.051, 0.230) .0021
4.2 (2.2, 10.6) .1944
VAS, visual analog scale.
measures mixed-effects model.
Table 5
Estimated EQ-5D Scores for Utility Loss by Age Group in Placebo Group and
Time Point during the Acute HZ Period (mTVC Conﬁrmed Cases)
Age Group, yr Time
Point
Least Squares
Means Estimate
Estimated
Utility Loss
P Value*
18-49 Pre-HZ .8523
Day 0 .5188 .3335 <.0001
Week 1 .5316 .3206 <.0001
Week 2 .6716 .1807 .0069
Week 3 .7607 .0916 .1870
Week 4 .7796 .0727 .3099
50 Pre-HZ .8003
Day 0 .5696 .2308 <.0001
Week 1 .5797 .2206 <.0001
Week 2 .6856 .1147 .0016
Week 3 .6696 .1307 .0005
Week 4 .7359 .0644 .0939
An EQ-5D value of 1 represents the best possible health state.
* P value is based on the repeated-measures mixed-effects model testing
the null hypothesis that the utility loss = 0.
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Recipients of HSCT have both an increased incidence and
severity of HZ [5-7,11,12]. In this trial, the overall efﬁcacy of RZV
in preventing HZ cases in autologous HSCT recipients was 68.2%
(95% CI, 55.6% to 77.5%) [21]. In this article, it was further dem-
onstrated that even when RZV failed to prevent HZ, vaccine
recipients experienced less severe pain, had a shorter duration
of pain, had less interference in ADLs, and had higher QoL scores
compared with the placebo group. Therefore, RZV not only pre-
vented HZ but also attenuated the severity of disease in RZV
recipients who developed HZ during this study. Consequently,
the overall efﬁcacy of RZV in reducing the burden of illness of
HZ and the burden of interference in ADLs exceeded 80%.
In the preceding ZOE-50 study and ZOE-70 pooled analysis,
in older adults, only 9 of 7340 and 25 of 7413 participants
developed HZ in the RZV groups, respectively, compared with
49 of 870 HSCT recipients in the current study [19-21]. The
magnitude of differences in pain scores, between the RZV and
placebo groups, in this present study during the acute HZ
period was consistent with the ZOE-50 and the ZOE-70 pooled
analysis. However, due to more individuals developing break-
through HZ in the ZOE-HSCT study, the statistical power toTable 6
HZ ZBPI Severity and Burden of Illness (Based on ZBPI Worst Pain) and Interference (Ba
RZV (n = 870)
Age Group, yr n m ZBPI Severity
of Illness
ZBPI Burden
of Illness
n
18-49 9 213 3.779 1.911 29
50 37 654 6.155 3.326 10
Total 46 867 5.572 2.960 13
Age Group, yr n m ZBPI Severity of
Interference
ZBPI Burden of
Interference
n
18-49 9 213 3.371 1.704 29
50 37 654 3.908 2.112 10
Total 46 867 3.776 2.007 13
Three and 2 participants in the RZV and placebo groups, respectively, had a conﬁrme
included in this table. The ZBPI severity of illness and severity of interference scores w
Activities of daily living scores, respectively, for participants with conﬁrmed HZ cases.
ZBPI burden of illness and burden of interference scores were calculated as the sum of
divided by the total follow-up in years. Higher scores represent more burden.
m indicates number of HZ cases in each vaccination group.detect signiﬁcant differences between the groups was higher
in the present study.
Although the ZBPI pain scores in the placebo group in ZOE-
50, ZOE-70 pooled analysis, and ZOE-HSCT studies appeared to
be similar during the ﬁrst week following rash onset, there
were differences in the median time to resolution of clinically
signiﬁcant pain (17, 22, and 31 days, respectively). The HZ bur-
den of illness scores in the placebo group of the ZOE-50 and
ZOE-70 pooled analysis were approximately 1.2 and 1.7,
respectively [29], compared with 16.9 in the ZOE-HSCT study.
As such, the HZ burden of illness is of a magnitude of approxi-
mately 10 times higher in autologous HSCT recipients, due to a
combination of both a higher incidence and a greater severity
of disease. Consequently, although the RZV VE is lower in
autologous HSCT recipients compared with healthy individuals
receiving RZV, the absolute reduction of HZ burden of illness is
meaningfully higher in autologous HSCT recipients.
Interestingly, in the placebo group of this study, the HZ bur-
den of illness and HZ burden of interference scores were lower
in younger rather than older autologous HSCT recipients
(Table 5); however, the utility losses appeared to be greater in
younger compared with older autologous HSCT recipients
(Table 4). As such, the reduction in HZ-related burden appears
important for both the young and older autologous HSCT
recipients.
The vaccine efﬁcacy reported in this study was similar to that
of a heat-inactivated varicella-zoster virus vaccine administered
to a similar HSCT population [30]. However, the latter was
achieved using a 4-dose schedule of the heat-inactivated vaccine
compared with a 2-dose schedule of RZV. Furthermore, the ﬁrst
dose of the 4-dose regimen was administered 1 month before
autologous HSCT, which can be logistically challenging [21].
This study has some limitations. The QoL endpoints were
either secondary or exploratory endpoints within the ZOE-
HSCT study, and as such, the study was not powered to show
speciﬁc differences in QoL parameters between the RZV and
placebo groups. Similarly, the study was not stratiﬁed or pow-
ered to draw conclusions by age groups.
This study of autologous HSCT recipients demonstrates that
RZV reduces both the frequency and severity of HZ. The HZ bur-
den of illness is dramatically higher in autologous HSCT recipi-
ents compared with healthier individuals included in the prior
ZOE studies. The results from this transplant study support the
ﬁndings from the previous ZOE studies in older adults andsed on ZBPI ADL) Scores (mTVC)
Placebo (n = 851)
m ZBPI Severity
of Illness
ZBPI Burden
of Illness
VE (95% CI), %
212 20.769 11.544 83.4 (63.4, 100.0)
4 637 31.348 18.857 82.4 (72.5, 92.3)
3 849 28.706 16.921 82.5 (73.6, 91.4)
m ZBPI Severity
of Interference
ZBPI Burden of
Interference
VE (95% CI), %
212 15.011 8.343 79.6 (51.3, 100.0)
4 637 21.355 12.846 83.6 (73.9, 93.3)
3 849 19.770 11.654 82.8 (73.3, 92.3)
d HZ episode but did not have an evaluable ZBPI score and were therefore not
ere calculated as the AUC, days 0 to 182, of the ZBPI worst pain scores and ZBPI
Participants without a conﬁrmed HZ case were allocated an AUC score of 0. The
the ZBPI severity of illness and severity of interference scores, respectively, and
2480 D. Curran et al. / Biol Blood Marrow Transplant 25 (2019) 24742481suggest that the RZV vaccine, in addition to being efﬁcacious in
preventing HZ, has a beneﬁt in attenuating the severity of HZ
disease in breakthrough cases, including in transplant recipients
younger than 50 years of age. In conclusion, RZV may represent
an additional prophylactic intervention in the care of patients
after autologous HSCT, who are at high risk for HZ.TRADEMARK
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